Clinical Trial Update: Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) [EARLY_Phase 1]

View source ↗

Summary

An early-phase imaging trial evaluating fluorescently labeled nivolumab-IRDye800 (Nivo800) for high-grade glioma, with the study currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• Glioma
• High-grade Glioma

Drugs mentioned

• Nivolumab-IRDye800 (Nivo800) (nivolumab-IRDye800 conjugate)
• nivolumab (nivolumab)

Snippet

Sponsor: Eben Rosenthal | Conditions: Brain Cancer, HGG | EARLY_Phase 1 | Status: NOT_YET_RECRUITING